Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-859: Pembrolizumab plus chemotherapy vs placebo plus chemotherapy in HER2-negative metastatic gastric/GEJ adenocarcinoma
jRCT2080224580Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Pembrolizumab plus chemotherapy (FP or CAPOX) with Placebo plus chemotherapy (FP or CAPOX) (2 arms). Primary endpoints: Overall survival (OS) and Progression-free survival (PFS). Started Mar 2019; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080224580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224580.